X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare VENUS REMEDIES with Panacea Biotech - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

VENUS REMEDIES vs PANACEA BIOTECH - Comparison Results

PANACEA BIOTECH 
   Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    VENUS REMEDIES PANACEA BIOTECH VENUS REMEDIES/
PANACEA BIOTECH
 
P/E (TTM) x -3.5 -6.2 - View Chart
P/BV x 0.1 1.9 7.0% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 VENUS REMEDIES   PANACEA BIOTECH
EQUITY SHARE DATA
    VENUS REMEDIES
Mar-18
PANACEA BIOTECH
Mar-14
VENUS REMEDIES/
PANACEA BIOTECH
5-Yr Chart
Click to enlarge
High Rs126149 84.7%   
Low Rs6182 74.2%   
Sales per share (Unadj.) Rs301.884.1 358.7%  
Earnings per share (Unadj.) Rs-24.9-18.3 135.9%  
Cash flow per share (Unadj.) Rs2.5-6.7 -38.0%  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs293.383.7 350.4%  
Shares outstanding (eoy) m12.3461.25 20.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.31.4 22.6%   
Avg P/E ratio x-3.8-6.3 59.6%  
P/CF ratio (eoy) x36.7-17.2 -213.1%  
Price / Book Value ratio x0.31.4 23.1%  
Dividend payout %00-   
Avg Mkt Cap Rs m1,1547,074 16.3%   
No. of employees `0000.92.8 33.6%   
Total wages/salary Rs m3931,449 27.1%   
Avg. sales/employee Rs Th4,026.11,874.1 214.8%   
Avg. wages/employee Rs Th425.0527.0 80.6%   
Avg. net profit/employee Rs Th-331.8-407.7 81.4%   
INCOME DATA
Net Sales Rs m3,7245,154 72.3%  
Other income Rs m23100 22.5%   
Total revenues Rs m3,7475,254 71.3%   
Gross profit Rs m395-766 -51.5%  
Depreciation Rs m338711 47.6%   
Interest Rs m3541,503 23.6%   
Profit before tax Rs m-275-2,881 9.6%   
Minority Interest Rs m011 0.0%   
Prior Period Items Rs m0-6 0.0%   
Extraordinary Inc (Exp) Rs m01,771 0.0%   
Tax Rs m3217 188.1%   
Profit after tax Rs m-307-1,121 27.4%  
Gross profit margin %10.6-14.9 -71.3%  
Effective tax rate %-11.5-0.6 1,968.1%   
Net profit margin %-8.2-21.8 37.9%  
BALANCE SHEET DATA
Current assets Rs m2,6383,810 69.2%   
Current liabilities Rs m2,3058,365 27.6%   
Net working cap to sales %8.9-88.4 -10.1%  
Current ratio x1.10.5 251.3%  
Inventory Days Days135156 87.0%  
Debtors Days Days4667 68.9%  
Net fixed assets Rs m4,87114,480 33.6%   
Share capital Rs m12361 201.3%   
"Free" reserves Rs m3,496903 387.1%   
Net worth Rs m3,6195,127 70.6%   
Long term debt Rs m1,3745,832 23.6%   
Total assets Rs m7,50919,433 38.6%  
Interest coverage x0.2-0.9 -24.3%   
Debt to equity ratio x0.41.1 33.4%  
Sales to assets ratio x0.50.3 187.0%   
Return on assets %0.62.0 32.1%  
Return on equity %-8.5-21.9 38.8%  
Return on capital %1.63.6 43.5%  
Exports to sales %024.5 0.0%   
Imports to sales %13.910.2 136.2%   
Exports (fob) Rs mNA1,264 0.0%   
Imports (cif) Rs m517525 98.4%   
Fx inflow Rs m01,539 0.0%   
Fx outflow Rs m517942 54.8%   
Net fx Rs m-517597 -86.5%   
CASH FLOW
From Operations Rs m514599 85.8%  
From Investments Rs m-123-438 28.1%  
From Financial Activity Rs m-387-303 127.9%  
Net Cashflow Rs m4-141 -3.0%  

Share Holding

Indian Promoters % 32.9 74.5 44.1%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.2 0.6 30.0%  
FIIs % 0.6 1.3 44.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 66.4 23.6 281.4%  
Shareholders   20,121 10,259 196.1%  
Pledged promoter(s) holding % 36.4 35.1 103.7%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare VENUS REMEDIES With:   PLETHICO PHARMA  BIOCON LTD  J.B.CHEMICALS  NATCO PHARMA  AJANTA PHARMA  

Compare VENUS REMEDIES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens 450 Points Down; All Eyes on State Election Results & Urjit Patel's Resignation(09:30 am)

Asian stock markets are higher today as Chinese and Hong Kong shares show gains. The Shanghai Composite is up 0.1% while the Hang Seng is also up 0.1%.

Related Views on News

PANACEA BIOTECH Announces Quarterly Results (2QFY19); Net Profit Down 1631.6% (Quarterly Result Update)

Nov 27, 2018 | Updated on Nov 27, 2018

For the quarter ended September 2018, PANACEA BIOTECH has posted a net profit of Rs 975 m (down 1631.6% YoY). Sales on the other hand came in at Rs 1 bn (down 22.3% YoY). Read on for a complete analysis of PANACEA BIOTECH's quarterly results.

VENUS REMEDIES Announces Quarterly Results (2QFY19); Net Profit Down 16.3% (Quarterly Result Update)

Nov 23, 2018 | Updated on Nov 23, 2018

For the quarter ended September 2018, VENUS REMEDIES has posted a net profit of Rs 8 m (down 16.3% YoY). Sales on the other hand came in at Rs 809 m (down 10.6% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My Top 7 Stocks to Buy Now(The 5 Minute Wrapup)

Nov 30, 2018

Of all the stocks that you could buy in this market, I've picked the seven best safe stocks that offer the ideal combination of safety and profit.

4 Rebound Stocks to Profit from the Current Small Cap Crash(Profit Hunter)

Dec 3, 2018

Indian small cap space is offering a discount season. Make sure you do not get too late to scoop up the bargains.

Reliance CPSE ETF (FFO3): Should You Invest?(Outside View)

Nov 29, 2018

Personalfn's analysis note on Reliance Mutual Fund Central Public Sector Enterprises Exchange Traded Fund (CPSE ETF). Should you subscribe?

Safety Beats Growth in 2018(Chart Of The Day)

Nov 30, 2018

With the markets turning up, these are my top 7 stock picks.

Looking For Higher Interest Rates on Bank FDs? Read This!(Outside View)

Dec 5, 2018

Credit disbursement to the productive sectors of the economy such as infrastructure, engineering, food processing, textiles, and chemicals, among others is rising.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

VENUS REMEDIES SHARE PRICE


Dec 11, 2018 12:19 PM

TRACK VENUS REMEDIES

  • Track your investment in VENUS REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON VENUS REMEDIES

VENUS REMEDIES 8-QTR ANALYSIS

COMPARE VENUS REMEDIES WITH

MARKET STATS